Astellas Pharma Inc. - Product Pipeline Review - 2015

  • ID: 3440593
  • Company Profile
  • 249 pages
  • Global Markets Direct
  • Astellas Pharma, Inc.
1 of 4
Astellas Pharma Inc. - Product Pipeline Review - 2015

Summary

The report ‘Astellas Pharma Inc. - Product Pipeline Review - 2015’, provides an overview of the Astellas Pharma Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Astellas Pharma Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Astellas Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Astellas Pharma Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Astellas Pharma Inc.’s pipeline products

Reasons to buy

- Evaluate Astellas Pharma Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Astellas Pharma Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Astellas Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Astellas Pharma Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Astellas Pharma Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Astellas Pharma Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Astellas Pharma Inc. Snapshot

Astellas Pharma Inc. Overview

Key Information

Key Facts

Astellas Pharma Inc. - Research and Development Overview

Key Therapeutic Areas

Astellas Pharma Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Astellas Pharma Inc. - Pipeline Products Glance

Astellas Pharma Inc. - Late Stage Pipeline Products

Astellas Pharma Inc. - Clinical Stage Pipeline Products

Astellas Pharma Inc. - Early Stage Pipeline Products

Astellas Pharma Inc. - Drug Profiles

capsaicin

evolocumab

tacrolimus ER

(mirabegron + solifenacin succinate)

amenamevir

ASP-0113

bendamustine hydrochloride

degarelix acetate

enzalutamide

fidaxomicin

gilteritinib fumarate

linaclotide

peficitinib hydrobromide

quetiapine fumarate ER

romosozumab

roxadustat

solifenacin succinate

ASP-1707

ASP-3662

ASP-8232

ASP-8273

ASP-8477

erlotinib hydrochloride

FG-2216

ipragliflozin

regadenoson

linsitinib

AGS-16C3F

AGS-67E

ASG-15ME

ASP-2205

ASP-2905

ASP-3325

ASP-4132

ASP-4345

ASP-5094

ASP-5633

ASP-5878

ASP-6282

ASP-6858

ASP-7962

enfortumab vedotin

mirabegron ER

OSI-930

AS-1069562

AS-1535907

AS-1669058

AS-1708727

AS-1940477

AS-2034178

AS-2077715

AS-2444697

AS-2521780

AS-2575959

AS-2690168

AS-2715348

AS-2795440

AS-288640100

ASP-1017

ASP-1645

ASP-3258

ASP-5736

ASP-6537

ASP-7663

ASP-9133

ASP-9726

FK-886

KB-425796C

Monoclonal Antibodies for Infectious Diseases

Monoclonal Antibody Conjugates for Oncology

OSI-296

respiratory syncytial virus vaccine

Small Molecule 2 for Epilepsy

Small Molecule 3 for Epilepsy

Small Molecule 4 for Epilepsy

Small Molecule for Epilepsy

Small Molecule to Antagonize IGF-1 Receptor for Colorectal Cancer

Small Molecule to Block N-type Calcium Channels for Neuropathic Pain

Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer

Small Molecule to Inhibit JAK3 for Transplantation

Small Molecule to Inhibit PDE10A for Schizophrenia

Small Molecule to Inhibit TAK1 for Ovarian Cancer

Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine

Small Molecules to Inhibit DAAO for Cognitive Disorders

Small Molecules to Inhibit RANKL for Osteoclastogenesis

Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema

AS-1468240

Drug For Alzheimer’s Disease

Drugs for Pancreatic Cancer

KB-425796A

Monoclonal Antibodies for Cancer

Small Molecules For Neglected Tropical Diseases

Small Molecules for Non-Neuromuscular and Neuromuscular Disorders

Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders

Small Molecules to Inhibit ACK1 for Cancer

Astellas Pharma Inc. - Pipeline Analysis

Astellas Pharma Inc. - Pipeline Products by Target

Astellas Pharma Inc. - Pipeline Products by Route of Administration

Astellas Pharma Inc. - Pipeline Products by Molecule Type

Astellas Pharma Inc. - Pipeline Products by Mechanism of Action

Astellas Pharma Inc. - Recent Pipeline Updates

Astellas Pharma Inc. - Dormant Projects

Astellas Pharma Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Astellas Pharma Inc. - Company Statement

Astellas Pharma Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Astellas Pharma Inc. - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Astellas Pharma Inc., Key Information

Astellas Pharma Inc., Key Facts

Astellas Pharma Inc. - Pipeline by Indication, 2015

Astellas Pharma Inc. - Pipeline by Stage of Development, 2015

Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2015

Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2015

Astellas Pharma Inc. - Partnered Products in Pipeline, 2015

Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2015

Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2015

Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015

Astellas Pharma Inc. - Pre-Registration, 2015

Astellas Pharma Inc. - Filing rejected/Withdrawn, 2015

Astellas Pharma Inc. - Phase III, 2015

Astellas Pharma Inc. - Phase II, 2015

Astellas Pharma Inc. - Phase I, 2015

Astellas Pharma Inc. - IND/CTA Filed, 2015

Astellas Pharma Inc. - Preclinical, 2015

Astellas Pharma Inc. - Discovery, 2015

Astellas Pharma Inc. - Pipeline by Target, 2015

Astellas Pharma Inc. - Pipeline by Route of Administration, 2015

Astellas Pharma Inc. - Pipeline by Molecule Type, 2015

Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2015

Astellas Pharma Inc. - Recent Pipeline Updates, 2015

Astellas Pharma Inc. - Dormant Developmental Projects,2015

Astellas Pharma Inc. - Discontinued Pipeline Products, 2015

Astellas Pharma Inc., Other Locations

Astellas Pharma Inc., Subsidiaries

Astellas Pharma Inc., Key Manufacturing Facilities

List of Figures

Astellas Pharma Inc. - Pipeline by Top 10 Indication, 2015

Astellas Pharma Inc. - Pipeline by Stage of Development, 2015

Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2015

Astellas Pharma Inc. - Partnered Products in Pipeline, 2015

Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2015

Astellas Pharma Inc. - Pipeline by Top 10 Target, 2015

Astellas Pharma Inc. - Pipeline by Top 10 Route of Administration, 2015

Astellas Pharma Inc. - Pipeline by Top 10 Molecule Type, 2015

Astellas Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll